Rua Bioscience Limited — Director's Dealing 2025

Jun 9, 2025

==> picture [357 x 38] intentionally omitted <==

Ongoing Disclosure Notice

Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

==> picture [506 x 559] intentionally omitted <==

----- Start of picture text ----- To NZX Limited; andName of listed issuer: Rua Bioscience Limited (Rua)Date this disclosure made: 9-Jun-25Date of last disclosure: 30-Sept-24Director or senior manager giving disclosureFull name(s): Teresa CiprianName of listed issuer: Rua BioscienceName of related body corporate (if applicable): N/APosition held in listed issuer: DirectorSummary of acquisition or disposal of relevant interest (excluding specified derivatives)Class of affected quoted financial products: Ordinary sharesNature of the affected relevant interest(s): ShareholderFor that relevant interest-Number held in class before acquisition or disposal: 525,000Number held in class after acquisition or disposal: 525,000N/A - new issue of warrants forCurrent registered holder(s):possible conversion to sharesRegistered holder(s) once transfers are registered: Teresa CiprianSummary of acquisition or disposal of specified derivatives relevant interest (if applicable)Type of affected derivative: WarrantsClass of underlying financial products: Ordinary SharesDetails of affected derivative-The notional value of the derivative (if any) or the notional amount of underlying financial 139,780 warrants. This issue ofproducts (if any): warrants represents 0.063% of thetotal ordinary shares on issue(being the percentage should allwarrants vest and be exercised). At$0.015 warrant price is $2096.70No consideration is payable forthe warrants. Cash consideration ofA statement as to whether the derivative is cash settled or physically settled:$0.015 per share is payable onexercise of the warrantsMaturity date of the derivative (if any): 13/05/2028Expiry date of the derivative(if any): 13/05/2028The price specified in the terms of the derivative (if any): $0.015----- End of picture text -----

Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: For that derivative,- Parties to the derivative: If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative:

N/A Teresa Ciprian N/A

Details of transactions giving rise to acquisition or disposal

Total number of transactions to which notice relates:

Details of transactions requiring disclosure-

Date of transaction: Nature of transaction: Name of any other party or parties to the transaction (if known): The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily by converted into a cash value, describe the consideration: Number of financial products to which the transaction related: If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during any period without written clearance (a closed period) include the following details— Whether relevant interests were acquired or disposed of during a closed period: Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period: Date of the prior written clearance (if any):

Summary of other relevant interests after acquisition or disposal:

Class of quoted financial products: Nature of relevant interest: For that relevant interest,- Number held in class: Current registered holder(s): For a derivative relevant interest,- Type of derivative:

1 14-May-25 Issue of warrants as part of a Debt Facility arrangement announced 13 May 2025 Rua Bioscience Limited No consideration is payable for the warrants. Cash consideration of $0.015 per share is payable on exercise of the warrants 139,780

No N/A N/A Ordinary Shares Registered holder 525,000 ordinary shares Teresa Ciprian

Details of derivative

The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):

A statement as to whether the derivative is cash settled or physically settled: Maturity date of the derivative (if any): Expiry date of the derivative (if any): The price's specified terms (if any):

139,780 warrants. This issue of warrants represents 0.063% of the total ordinary shares on issue No consideration is payable for the warrants. Cash consideration of $0.015 per share is payable on exercise of the warrants 13/05/2028 13/05/2028 $0.015

Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the N/A underlying financial products: For that derivative relevant interest,- Parties to the derivative: Teresa Ciprian If the director or senior manager is not a party to the derivative, the nature of the N/A relevant interest in the derivative: Certification I, certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made. Signature of person authorised to sign on behalf of director or officer: Date of signature: 9/06/2025 Name and title of authorised person: Paul Naske, CEO